This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Occurrence After Treatment With Melphalan for Multiple Myeloma

Richard Bell, MRACP; John R. Sullivan, MD, FRACP; David J. Fone, MD, FRACP; Thomas H. Hurley, MD, FRACP

JAMA. 1976;236(14):1609-1610.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

IT HAS been advocated that adjuvant cytotoxic chemotherapy with melphalan after mastectomy may be the preferred form of management of primary carcinoma of the breast with pathologically positive axillary nodes.¹ We report two patients treated with melphalan in whom carcinoma of the breast subsequently developed.

Report of Cases

CASE 1.—

A 68-year-old woman had back pain in January 1974. A diagnosis of multiple myeloma was made based on a monoclonal peak on serum protein electrophoresis, a total protein value of 11.3 gm/100 ml, and a bone marrow aspirate that showed 60% plasma cells. The patient was treated with intermittent doses of melphalan and prednisolone.²

In April 1975, obstructive jaundice developed. A liver biopsy specimen showed evidence of extrahepatic biliary obstruction. A percutaneous transhepatic cholangiogram showed dilated hepatic ducts, with complete obstruction in the common bile duct. At laparotomy, a carcinoma of the head of the pancreas was found; . . . [Full Text PDF of this Article]

Author Affiliations
From Medical Unit 2, Royal Melbourne Hospital, Melbourne.

Footnotes
Reprint requests to the Special Hematology Clinic, Royal Melbourne Hospital, Melbourne, Victoria, Australia 3050 (Dr Sullivan).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?